Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does AFLIBERCEPT Cause Malignant neoplasm progression? 39 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 39 reports of Malignant neoplasm progression have been filed in association with AFLIBERCEPT (EYLEA). This represents 0.2% of all adverse event reports for AFLIBERCEPT.

39
Reports of Malignant neoplasm progression with AFLIBERCEPT
0.2%
of all AFLIBERCEPT reports
22
Deaths
10
Hospitalizations

How Dangerous Is Malignant neoplasm progression From AFLIBERCEPT?

Of the 39 reports, 22 (56.4%) resulted in death, 10 (25.6%) required hospitalization, and 3 (7.7%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for AFLIBERCEPT. However, 39 reports have been filed with the FAERS database.

What Other Side Effects Does AFLIBERCEPT Cause?

Death (7,669) Visual impairment (1,836) Blindness (1,337) Endophthalmitis (1,289) Off label use (1,156) Eye pain (1,057) Product dose omission issue (1,051) Blindness unilateral (1,012) Vision blurred (1,012) Visual acuity reduced (993)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which AFLIBERCEPT Alternatives Have Lower Malignant neoplasm progression Risk?

AFLIBERCEPT vs AGALSIDASE ALFA AFLIBERCEPT vs AGALSIDASE BETA AFLIBERCEPT vs AGOMELATINE AFLIBERCEPT vs ALAWAY AFLIBERCEPT vs ALBENDAZOLE

Related Pages

AFLIBERCEPT Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression AFLIBERCEPT Demographics